Workshop on leveraging Global Fund proposals for TB, HIV and Malaria in South-East Asia Region countries towards UHC and elimination targets

Overview

The Global Fund has launched the process for submission of funding request under the 2020- 2022 cycle. All eligible countries with grants ending in 2020 have been tentatively designated to 3 application windows in 2020 (in March, May and August2020). Nine out of the 11 Member States in the Region will be submitting funding request during the 2020-2022 replenishment cycle of the Global Fund. DPR Korea has recently reengaged with the Global Fund and is in the process of receiving a grant. Maldives has not received any allocation.

In the allocation period 2020 -2022 to countries of the Region (excluding Maldives and DPRK) for the three diseases is over USD 1.37 billion, with India, Indonesia and Myanmar the top three countries. Disease split is 35% for HIV, 50% for TB and rest for malaria. Over and above the allocations, countries under notification from the Global Fund are also able to access additional funding under Catalytic investment funding, matching-funds, prioritize above allocation request and reprogramming of exiting funds WHO at all three levels continues to work closely with the Global Fund.

WHO at the country level are actively involved in the Country Coordination Mechanism. WHO through its country office staff and additionally recruited Technical Consultants provide support to country partners in facilitating national dialogues on the three diseases, conducting monitoring and evaluation missions, review and revision of national strategic plans and drafting of national proposals for submission to the Global Fund. WCOs are also actively involved in the implementation of GF grants at the country level including having signed MOUs for active implementation. Review conducted by the Global Fund showed that between 2012-2017, WCOs in the SEAR received over USD 30 million from the GF grants to countries for undertaking activities and for staff and management cost.